Conference Preview: American College of Gastroenterology’s 2025 Annual Scientific Meeting

The American College of Gastroenterology (ACG)’s 2025 Annual Scientific Meeting kicks off in Phoenix, Arizona, on Monday, October 27, 2025. Coined as the premier GI clinical event of the year, the 3-day conference will feature the hottest topics in clinical GI, hepatology, and endoscopy, with updates delivered by internationally known faculty and rising stars in each of these spaces.

The agenda for this year’s meeting will provide a diverse schedule of didactic sessions, clinical symposia, and featured lectures addressing the educational needs and priorities of clinical GI practitioners. The HCPLive editorial team will be on-site at the meeting, providing written coverage of practice-shifting data as well as interviews with key experts.

You can keep up with HCPLive’s comprehensive conference coverage here. Check out what can be expected from this year’s meeting below:

Expert Interviews

Evan Dellon, MD, who will discuss data on dupilumab for the treatment of eosinophilic esophagitis (EoE) from the phase 3 EoE KIDS and LIBERTY EoE TREET studies. Dellon is a professor in the division of gastroenterology and hepatology and director of the Center for Esophageal Diseases and Swallowing at UNC School of Medicine.

Marlyn Mayo, MD, who will review findings from a pooled analysis of the RESPONSE and ENHANCE studies assessing the impact of seladelpar on pruritus in patients with primary biliary cholangitis (PBC). Mayo is a professor of internal medicine at UT Southwestern Medical Center.

Laurie Keefer, PhD, who will explain results from the ASPIRE-CD study examining the real-world impact of treatment with risankizumab on health-related quality of life in adults With Crohn’s disease. Keefer is a clinical health psychologist and professor of medicine, Psychiatry and Biomedical Sciences at Icahn School of Medicine at Mount Sinai.

Akram Ahmad, MD, who will discuss data from the OCULUS trial on the impact of holding versus continuing GLP-1 or GIP agonists prior to upper endoscopy. Ahmad is a gastroenterology fellow at Cleveland Clinic Florida.

Trials to Watch

There is a plethora of clinical trial data being presented at ACG 2025. HCPLive crafted a curated list of 6 trials to watch from the upcoming meeting:

1. A Placebo-Controlled Trial of CGRP Antagonist Rimegepant on Visceral Sensation and Symptoms in Participants With Non-Constipated IBS Pain

Presentation Time: 3:35 PM - 3:45 PM PDT on Tuesday, October 28, 2025

Presenter: Ayah Matar, MD

Background Info:

Calcitonin gene-related peptide (CGRP) is a neurotransmitter in digestive organs and is expressed by visceral afferents. Rimegepant, a CGRP receptor antagonist, is approved for episodic and preventive treatment of migraine pain. Investigators conducted a randomized, double-blind, placebo-controlled trial (NCT06221111) of oral rimegepant, 75mg every other day, to evaluate its safety and efficacy on abdominal pain (AP), bowel movements, rectal compliance and sensation, gastrointestinal and colonic transit in participants with non-constipation irritable bowel syndrome (IBS) with AP.

2. Persistent Improvement in Dysphagia Symptoms for 52 Weeks Following a Single Administration of EP-104GI in RESOLVE, an Ongoing Phase 1b/2 Trial in Eosinophilic Esophagitis

Presentation Time: 10:00 AM - 10:10 AM PDT on Wednesday, October 29, 2025

Presenter: Hin Hin Ko, MD, BSC(Pharm)

Background Info:

Patients with EoE experience esophageal inflammation leading to tissue remodeling and potentially severe symptoms of dysphagia, pain and food impaction. EP-104GI was designed as an injectable, long-acting submucosal fluticasone propionate formulation.

RESOLVE is an ongoing Phase 1b/2, multicenter, open-label, dose-escalation trial evaluating the safety, tolerability, and efficacy of EP-104GI in adult participants with EoE. Data being presented at ACG 2025 assesses improvements in dysphagia among the first cohort to complete an extended follow-up period of 52 weeks after a single administration of EP-104GI as part of RESOLVE.

3. Efficacy and Safety of Obefazimod in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Two, Phase 3, Randomised, Double-Blind, Placebo-Controlled, 8-Week Induction Trials (ABTECT 1 & 2)

Presentation Time: 9:50 AM - 10:00 AM PDT on Wednesday, October 29, 2025

Presenter: Bruce Sands, MD

Background Info:

Obefazimod, an oral, once-daily, small molecule which enhances expression of microRNA-124, was studied in patients with moderately to severely active ulcerative colitis (UC) in phase 2 induction trials and in subsequent open-label maintenance studies1. Data being presented at ACG 2025 reports the efficacy and safety of 2 phase 3, 8-week induction trials in adult patients with UC from ABTECT-1 and ABTECT-2.

4. AVB-114 Demonstrates Clinical Benefit in Persistent Crohn’s Perianal Fistulas: Results From the Multicenter Randomized STOMP2 Trial

Presentation Time: 10:00 AM - 10:10 AM PDT on Wednesday, October 29, 2025

Presenter: David Schwartz, MD

Background Info:

Nearly a quarter of patients with CD will develop a perianal fistula. Despite the use of advanced therapies, the majority of these patients will not achieve complete closure of their fistula tracts. Recognizing this clinical dilemma, the STOMP2 trial sought to determine whether the implantable autologous cell therapy AVB-114 is effective in inducing remission of persistent Crohn’s perianal fistulas versus standard of care.

5. Feasibility of Targeted Pancreatic Cooling in Acute Pancreatitis: A Prospective, First-in-Human, Multi-Center Study

Presentation Time: 3:35 PM - 3:45 PM PDT on Tuesday, October 28, 2025

Presenter: Walter Park, MD

Background Info:

Patients with acute pancreatitis who presented within 72 hours of symptom onset were recruited to participate in this prospective, single arm, multicenter, first in human study of a novel, minimally invasive nasogastric catheter. Data regarding technical success (catheter placement, cooling) and incidence of adverse events (AE) will be presented at ACG 2025.

6. From ED to EoE: Improving Practices for Timely Diagnosis

Presentation Time: 9:50 AM - 10:00 AM PDT on Wednesday, October 29, 2025

Presenter: Rosa Yu, MD

Background Info:

Early diagnosis of EoE is critical for timely treatment and avoidance of complications. With rising prevalence and frequent diagnostic delays, adults with undiagnosed EoE may present to the emergency department with esophageal food impaction (EFI) or dysphagia. Prompt endoscopy (EGD) with biopsies, ideally concurrent with treatment of impaction, is essential to confirm diagnosis and prevent loss to follow-up, ensuring optimal care.

Findings from a quality improvement project leveraging the Model for Improvement centering on biopsies during index EGDs for EFI and improving follow-up care for patients with dysphagia will be presented at ACG 2025.